We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


GlaxoSmithKline Purchases Illumina's HumanHap550 BeadChips for Large Scale Whole Genome Association Studies

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

Illumina, Inc. has announced that it entered into a multi-million dollar agreement with GlaxoSmithKline (GSK) for the purchase of 1,000 HumanHap550 BeadChips to be run at an undisclosed third-party facility and the addition of a statement of work to utilize Illumina's Fast-Track Genotyping Service to process approximately 4,000 disease samples for pharmacogenetics application.

According to Illumina, by the end of 2006, it will have genotyped more than 15,000 samples and reported nearly 3.5 billion genotypes to GSK.

"This purchase follows shortly after GlaxoSmithKline expanded their initial scope of work for a multi-year, genotyping services agreement with Illumina, demonstrating their continued uptake of our technology," said Jay Flatley, Illumina President and Chief Executive Officer.